Compare CREX & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CREX | SCYX |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 37.0M |
| IPO Year | 2015 | 2014 |
| Metric | CREX | SCYX |
|---|---|---|
| Price | $3.11 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 27.1K | ★ 234.2K |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.86 | ★ 61.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,437,000.00 | $257,000.00 |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $2.19 | $0.57 |
| 52 Week High | $4.42 | $5.62 |
| Indicator | CREX | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 34.98 | 63.83 |
| Support Level | $2.67 | $0.65 |
| Resistance Level | $3.09 | $5.62 |
| Average True Range (ATR) | 0.16 | 0.46 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 1.49 | 78.61 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The company operates in one reportable segment, marketing technology solutions. It offers solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks, along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media. Geographically, the company generates maximum revenue from the United States, and the rest from Canada.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.